Eva Szigethy1, Elyse Kenney2, Johanna Carpenter2, Diana M Hardy2, Diane Fairclough2, Athos Bousvaros2, David Keljo2, John Weisz2, William R Beardslee2, Robert Noll2, David Ray DeMASO2. 1. Drs. Szigethy, Keljo, and Noll and Ms. Hardy are with Children's Hospital of Pittsburgh/University of Pittsburgh Medical Center, Departments of Psychiatry and Pediatrics; Drs. Bousvaros, Beardslee, DeMaso, Ms. Kenney, and Ms. Carpenter are with Children's Hospital Boston/Harvard Medical School, Departments of Psychiatry and Pediatrics; Dr. Fairclough is with the University of Colorado Health Sciences Center, Department of Preventive Medicine and Biometry; Dr. Weisz is with the Judge Baker Children's Center/Harvard Medical School. Electronic address: szigethye@upmc.edu. 2. Drs. Szigethy, Keljo, and Noll and Ms. Hardy are with Children's Hospital of Pittsburgh/University of Pittsburgh Medical Center, Departments of Psychiatry and Pediatrics; Drs. Bousvaros, Beardslee, DeMaso, Ms. Kenney, and Ms. Carpenter are with Children's Hospital Boston/Harvard Medical School, Departments of Psychiatry and Pediatrics; Dr. Fairclough is with the University of Colorado Health Sciences Center, Department of Preventive Medicine and Biometry; Dr. Weisz is with the Judge Baker Children's Center/Harvard Medical School.
Abstract
OBJECTIVE: To examine the feasibility and efficacy of a manual-based cognitive-behavioral therapy (CBT) in reducing depressive symptomatology in adolescents with inflammatory bowel disease (IBD). Primary and Secondary Control Enhancement Therapy-Physical Illness (PASCET-PI) modified for youths with IBD was compared to treatment as usual (TAU), plus an information sheet about depression, without therapist contact using assessable patient analysis. METHOD: Following assessment, participants 11 to 17 years old with IBD and mild to moderate subsyndromal depression were randomly assigned to PASCET-PI (n = 22) or comparison treatment (n = 19). Primary outcome measures at baseline (T1) and 12 to 14 weeks posttreatment (T2) were Children's Depression Inventory (child/parent report), Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), Children's Global Assessment Scale, and Perceived Control Scale for Children. RESULTS: The PASCET-PI group showed significantly greater improvement in Children's Depression Inventory (child/parent report), Children's Global Assessment Scale, and Perceived Control Scale for Children posttreatment than the comparison group. CONCLUSIONS: Screening and treatment of depressive symptoms in pediatric settings is feasible. PASCET-PI may be an efficacious intervention for subsyndromal depression in adolescents with IBD, although comparison with a more active treatment is necessary to attribute the improvement to PASCET-PI. CLINICAL TRIAL REGISTRATION INFORMATION: URL: http://clinicaltrials.gov. Unique identifier: NCT00446238.
RCT Entities:
OBJECTIVE: To examine the feasibility and efficacy of a manual-based cognitive-behavioral therapy (CBT) in reducing depressive symptomatology in adolescents with inflammatory bowel disease (IBD). Primary and Secondary Control Enhancement Therapy-Physical Illness (PASCET-PI) modified for youths with IBD was compared to treatment as usual (TAU), plus an information sheet about depression, without therapist contact using assessable patient analysis. METHOD: Following assessment, participants 11 to 17 years old with IBD and mild to moderate subsyndromal depression were randomly assigned to PASCET-PI (n = 22) or comparison treatment (n = 19). Primary outcome measures at baseline (T1) and 12 to 14 weeks posttreatment (T2) were Children's Depression Inventory (child/parent report), Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), Children's Global Assessment Scale, and Perceived Control Scale for Children. RESULTS: The PASCET-PI group showed significantly greater improvement in Children's Depression Inventory (child/parent report), Children's Global Assessment Scale, and Perceived Control Scale for Children posttreatment than the comparison group. CONCLUSIONS: Screening and treatment of depressive symptoms in pediatric settings is feasible. PASCET-PI may be an efficacious intervention for subsyndromal depression in adolescents with IBD, although comparison with a more active treatment is necessary to attribute the improvement to PASCET-PI. CLINICAL TRIAL REGISTRATION INFORMATION: URL: http://clinicaltrials.gov. Unique identifier: NCT00446238.
Authors: Mark Hyman Rapaport; Andrew A Nierenberg; Robert Howland; Christina Dording; Pamela J Schettler; David Mischoulon Journal: J Psychiatr Res Date: 2011-05-31 Impact factor: 4.791
Authors: Luuk Stapersma; Gertrude van den Brink; Jan van der Ende; Eva M Szigethy; Ruud Beukers; Thea A Korpershoek; Sabine D M Theuns-Valks; Manon H J Hillegers; Johanna C Escher; Elisabeth M W J Utens Journal: J Pediatr Psychol Date: 2018-10-01
Authors: Arvind I Srinath; Alka Goyal; Lori A Zimmerman; Melissa C Newara; Margaret A Kirshner; Francis Nicole McCarthy; David Keljo; David Binion; Athos Bousvaros; David R DeMaso; Ada Youk; Eva M Szigethy Journal: Inflamm Bowel Dis Date: 2014-08 Impact factor: 5.325
Authors: Eva Szigethy; Simona I Bujoreanu; Ada O Youk; John Weisz; David Benhayon; Diane Fairclough; Peter Ducharme; Joseph Gonzalez-Heydrich; David Keljo; Arvind Srinath; Athos Bousvaros; Margaret Kirshner; Melissa Newara; David Kupfer; David R DeMaso Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-05-10 Impact factor: 8.829